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Editorial Comment 
Ergonovine Echocardiography for 
Coronary Spasm: Facts and 
Wishful Thinking* 
CARL J. PEPINE, MD, FACC 
Gainesville, Florida 
In this issue of the Journal, Song et al. (1) describe their 
enthusiasm for a novel noninvasive t st strategy as a screening 
evaluation for the diagnosis of coronary artery spasm. Their 
strategy was designed to confirm the diagnosis of coronary 
spasm among patients with chest pain syndromes uggesting 
variant angina. Patients with myocardial infarction, unstable 
angina, bundle branch block or rhythm disturbances were 
excluded. After discontinuation f cardioactive drugs, a non- 
invasive stress test (exercise electrocardiogram [ECG] or 
thallium-201 imaging) was applied. Echocardiography was 
performed in patients with negative noninvasive stress test 
results. In patients with acceptable acoustic windows, ergono- 
vine was administered intravenously, in bolus doses, until 
either ischemia or a total dose of 0.35 mg occurred. Develop- 
ment of either eversible ECG ST segment changes or regional 
wall motion abnormalities was taken to represent criteria for 
coronary spasm. The authors report reasonable specificity and 
sensitivity and no complications in 80 patients compared with 
that for provocative t sting done during coronary angiography. 
The first consideration for any test for coronary spasm must 
be the safety of the test. Clearly, one cannot judge safety in 80 
patients. There is a small but finite risk for adverse outcome 
associated with ergonovine testing when performed in the 
catheterization laboratory (2). Abrupt occlusion, profound 
hypotension or ventricular tachycardia/ventricular fib illation 
that does not respond to intravenous nitroglycerin or calcium 
antagonists may develop. Presumably, this is the result of more 
intense spasm, plaque disruption and thrombosis at or near 
sites of spasm, as suggested by a recently developed experi- 
mental model proposed by Picon et al. (3) using a triggering 
vasoconstrictor substance. Other experimental models indicate 
that intense vasoconstriction (e.g., vasoconstrictor applied 
topically to arteries) may result in changes in endothelial 
structure (4-6) and function that could also favor platelet 
aggregation a d coagulation at the lumen surface. Refractory 
coronary spasm requiring intracoronary nitroglycerin for relief 
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has been described by us (7,8) and others (2), and sometimes 
there is need for an intracoronary calcium antagonist or even 
emergency percutaneous transluminal coronary angioplasty. 
During a noninvasive t st, if refractory coronary spasm were to 
occur at the site of ergonovine-induced spasm, a serious 
problem could result with no direct access to the coronary 
arteries. Even if such a problem occurred in only 1 of 1,000 
patients with spasm, the outcome could be catastrophic. How- 
ever, patients undergoing testing in a catheterization labora- 
tory would have the option of intracoronary administration f 
not only nitroglycerin and calcium antagonists, but also throm- 
bolytic agents as well as balloon angioplasty if needed. 
The second consideration with any test is its value as a 
strategy in patient management. As a general principle, diag- 
nostic tests are most effective when utilized in patients with an 
intermediate pretest likelihood of the suspected condition. 
Conversely, a test is less indicated at extremes of pretest 
likelihood. The authors identified angiographic evidence for 
coronary spasm in 56 (74%) of the 76 patients examined in a 
1-year period. Thus, this is not a cohort where anything less 
than a perfect est result is likely to provide additional useful- 
ness. These data suggest that the patients chosen for evalua- 
tion of the new test were highly selected (e.g., study population 
was enriched in patients with coronary spasm). This high 
percentage also raises the issue of selection bias related to how 
the patients were chosen to evaluate this new test. How the test 
would perform in the usual population of patients with coro- 
nary artery disease undergoing evaluation in our country is 
unknown. Although coronary spasm and the need to know 
were prominent questions two decades ago, this issue is no 
longer common in contemporary practice, perhaps because of 
the frequent use of calcium antagonists, better nitrate regi- 
mens or attenuations in the virulence of coronary artery 
disease processes. Questions about coronary spasm contribut- 
ing to a clinical syndrome have become relatively infrequent. 
Furthermore, the few patients that we are asked to evaluate at 
present, relative to possible coronary spasm, often have very 
refractory chest pain syndromes that have eluded multiple 
physician evaluations. It is unlikely that a noninvasive t st, with 
unknown sensitivity and specificity in such a population, as well 
as uncertainties about safety, will satisfy the requirement for a 
definitive valuation to sort out such a complex clinical prob- 
lem. However, this is speculation and what is needed is a study 
that investigates the relative usefulness of a strategy of man- 
agement that is guided by a noninvasive test for coronary 
spasm compared with a strategy where such a test is omitted. 
Said another way, Is this knowledge of value in the subsequent 
cost-effective management of such patients? Certainly, knowl- 
edge about the presence or absence of important coronary 
disease is important in certain patients, but such patients are 
likely to undergo coronary angiography anyway, and if needed, 
an invasive test for spasm may then be carried out. 
Until these issues are addressed, my recommendation is 
that in the few patients requiring atest for spasm, it is probably 
safer to perform such a test in the catheterization laboratory. 
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This would reserve the new test for the very few patients that 
have either had a recent coronary angiogram or in whom, for 
some reason, knowledge of coronary anatomy would not be 
needed. In my view, it is therefore wishful thinking to believe 
that this new noninvasive test for spasm could have much 
clinical utility even if the facts about safety, sensitivity and 
specificity were resolved. 
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